CRVS - Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition | Benzinga
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL), at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 9-12, 2023.
Details regarding the poster presentation, which will be available in the poster hall and via the virtual event platform, are as follows:
Date and Time: Saturday, December 9, 2023, 5:30 PM PT
Title: Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma
Abstract #: 1442
Presenter: Dr. Ning Ding, Peking University Cancer Hospital & Institute, Beijing, China
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company's lead product candidate is soquelitinib, an investigational, oral, ...